Investment

Scientist looking through microscope
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Automation / robotics #Financing #Fundraising #Iktos #Investment

AI and robotics drug discovery company raises €15.5M

Iktos has raised €15.5m in a Series A funding round to expand its artificial intelligence-based drug discovery technologies and solutions. The round was co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital. The financing will enable the company to launch Iktos Robotics; a drug… Read More

#Business & Investment #News

Plague bacterium Yersinia pestis, scientifically accurate 3D illustration showing structure of the cell with DNA, plasmids and ribosomes
#Cancer research #CureLab Oncology #Gene therapy #Investment #Oncology #Plasmid DNA

Oncology company receives $3M from biotech investor

Dr John Ballantyne, co-founder of Aldevron, has invested $3 million in CureLab Oncology and CureLab Veterinary. The two sister companies have developed an anti-cancer and anti-inflammatory drug that was contract-manufactured by Aldevron at the time Dr Ballantyne served there as chief scientific officer. Both CureLab Oncology and CureLab Veterinary are… Read More

#Business & Investment #News

Start-up business
#BioInnovation Institute #Drug discovery #Investment #Life sciences #Start-ups

Institiute gives a boost to five new life science start-ups

Five drug discovery companies have entered the BioInnovation Institute’s (BII) Venture Lab acceleration programme for early-stage companies as part of a cohort of ten new members.  The 12-month Venture Lab programme is designed to support start-up companies with business acceleration, scientific, and team development, and provides a… Read More

#News #Start-up Zone

#Antivirals #Drug development #Drug discovery #Henipavirus #Investment

Millions invested in antiviral medicines for future pandemics 

The partners in the Pandemic Antiviral Discovery (PAD) initiative have announced grants totalling more than $26 million for 14 research projects aimed at facilitating early-stage development of drugs to treat henipavirus infection and disease in humans.  These grants mark the majority of the first investments to come… Read More

#News

Neuron and antibodies
#AI / data analytics / healthtech / informatics #Antibodies #Antiverse #Drug discovery #Funding #Investment #Machine learning

AI company raises $3m to develop antibodies targeting GPCRs

Antiverse has successfully identified functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity.  The company has raised $3 million in funding, which will enable in-house development of the antibodies showing the highest affinity blocking function. The antibodies were identified using Antiverse’s proprietary… Read More

#News

Senior couple jogging
#Age-related diseases (ARDs) #Five Alarm Bio #Investment #Seed funding #Start-ups

Anti-ageing therapeutics company completes seed funding

Five Alarm Bio (FAB) has completed a seed investment round, raising over £500K ($605K). The funding will drive proprietary research into novel compounds that extend healthy lifespan of cells and tissues, with therapeutic potential across a broad range of age-related diseases. Investors include Cambridge Angels, Meltwind, o2h Ventures, and SyndicateRoom,… Read More

#News #Start-up Zone

#Funding #Immunology / Virology & Vaccines #Investment #mRNA #mRNA-based vaccines

Funding injection for Strep A vaccine research

A research effort to develop an mRNA vaccine against Group A Streptococcus (Strep A) has secured almost $8 million in funding.  The Leducq Foundation has announced support for the University of Queensland-led project that could reduce Strep A infections, which cause more than 500,000 deaths a year… Read More

#News

Researcher pipetting samples in microplate
#Drug delivery #Funding #Genetics #Genetics / genomics #Investment #Start-ups

Start-up aims to advance transformative genetic medicines

Aera Therapeutics has launched with a vision to “unlock the potential of genetic medicines across a wide range of modalities and therapeutic areas”.   The company’s delivery platform is based on research conducted in the laboratory of scientific founder Feng Zhang and aims to address the limitations of… Read More

#News #Start-up Zone

#DNA #Financing #Funding #Investment #Synthetic biology

$24 million funding to accelerate synthetic biology research

Evonetix has completed a $24 million financing round, extending its total series B funding to over $54 million.   The fundraise was led by existing investor Foresite Capital, with Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence also participating in the round.  The investment will enable the continued development… Read More

#Business & Investment #News

UK financial markets
#BioIndustry Association #Biologics / Biotechnology #Clarivate #Investment #Market reporting #Mergers and acquisitions #Private investment #Seed funding #UK

UK biotech investment drops after bumper years

Investment in UK biotech has fallen from £4.5 billion in 2021 to just £1.8 billion in 2022, mirroring the global economic downturn impacting all sectors.  However, venture capital investment in the sector was the third-best year recorded for the UK, with £1.2 billion raised, new analysis from the UK BioIndustry… Read More

#Business & Investment #News

T cells attack a cancer cell
#Financing #Grey Wolf Therapeutics #Immuno-oncology #Investment #Oncology #T cell activation

$49 million raised to fund original immuno-oncology approach

Grey Wolf Therapeutics has closed an oversubscribed $49 million Series B financing co-led by Pfizer Ventures and Earlybird Venture Capital, with investment from Oxford Science Enterprises, British Patient Capital, Canaan and Andera Partners.   Proceeds will support the continued development of the company’s first-of-its-kind immuno-oncology approaches designed to overcome key resistance… Read More

#Business & Investment #News #Start-up Zone

Gene therapy
#Cell and gene therapy #Gene therapy #Investment #Muscular dystrophy #Seed funding #Start-ups

$5 million raised towards gene therapies for muscular diseases

Myosana Therapeutics has completed a seed funding round totalling over $5 million led by investor John Ballantyne.  The capital will go towards developing Myosana’s gene therapy platform for neuromuscular and cardiac disease, with the goal of identifying the first development candidate for Duchenne muscular dystrophy by 2025.  “Built on decades… Read More

#Business & Investment #News #Start-up Zone

microRNA
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Funding #Investment #Machine learning #Molecular Biology #RNA #Start-ups

$35 million to advance AI-driven RNA structure platform

Atomic AI, a biotechnology company fusing machine learning with structural biology to unlock RNA drug discovery, launched today with a $35 million Series A round.  The financing was led by Playground Global, with participation from 8VC, Factory HQ, Greylock, NotBoring, AME Cloud Ventures, and renowned angel investors including GitHub ex-CEO… Read More

#Business & Investment #News #Start-up Zone

Cancer research
#Cancer immunotherapy #Cancer research #Funding #Immunotherapy #Investment #ISA Pharmaceuticals #Oncology #Ophthalmology #Synthetic biology

$5 million to fund trial of therapy for uveal melanoma

Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA Pharmaceuticals’ PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.  Cancer Focus Fund was established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and… Read More

#Business & Investment #Cancer Research #News

Protein
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #BioInnovation Institute #Biologics / Biotechnology #Investment #Proteins #Start-ups

Therapeutic protein project joins Bio Studio programme

A project creating a new class of therapeutic proteins to modulate cell signalling has been accepted into the BioInnovation Institute (BII) Bio Studio programme. The project is based on recent breakthroughs in artificial intelligence (AI) and protein design, and uses methods pioneered by David Baker’s laboratory at the University of… Read More

#News #Start-up Zone

#Biologics / Biotechnology #Cancer research #Financing #Investment #Oncology #RNA

Biotech company raises $30M to target RNA modifying enzymes

Clinical biotechnology company Storm Therapeutics has successfully completed a USD $30 million Series B financing round.  The investment allows the company to focus on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases.  The financing was co-led by existing investors M Ventures,… Read More

#Business & Investment #News